Aurora Civati

Aurora Civati

Auto-generated profile, based on publicly available information

Aurora Civati

Department of Biomedical and Clinical Sciences, Università Degli Studi di Milano , Milan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2024 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
Cheli StefaniaCheli Stefania
Cheli Stefania
ATAlessandro Torre
Alessandro Torre
MSMarco Schiuma
Marco Schiuma
CMCristina Montrasio
Cristina Montrasio
ACAurora Civati
Aurora Civati
Spinello AntinoriSpinello Antinori
Spinello Antinori
Background: Under standard therapies, the incidence of drug-induced liver injury (DILI) in patients with tuberculosis ranges from 2% to 28%. Numerous studies have identified the risk factors for antituberculosis DILI; however, none have been conducted in a multiethnic real-world setting. The primary outcome of the current study was to identify the risk factors that could be used as the best predictors of DILI in a multiethnic cohort. Methods: A nested case-control study was conducted in patients at the tuberculosis clinic of Luigi Sacco Hospital in Milan. Results: The study included 102 patients (mean age [SD], 45.6 [15.6] years). For each patient with hepatotoxicity, 2 controls were matched for sex, age, body mass index, tuberculosis/tuberculosis infection diagnosis, and index date. We found that N-acetyltransferase 2 gene (NAT2) slow acetylator status was the best independent predictor of DILI (odds ratio, 5.97 [95% confidence interval, 1.38–25.76]; P = .02]. Conclusions: NAT2 genotype–guided dosing may help optimize antituberculosis drug treatment and prevent treatment failure. Clinical Trials Registration: ClinicalTrials.gov NCT06539455